Relationship Between Self-compassion and Treatment Adherence in Schizophrenic Spectrum Disorders (CompaSchizo)

Treatment adherence is defined by the World Health Organisation (WHO) as the extent to which the patient's history of therapeutic drug-taking coincides with the prescribed treatment. In patients suffering from psychiatrical diseases, especially in those who are suffering from schizophrenic spectrum disorders, the quality of treatment adherence has to be improved. Indeed, non adherance to anti-psychotic treatment increases the risk of hospitalization, of substance use, violent behaviour and of functionnal and cognitif impairment. Selfcompassion, which involves being touched by and open to one's own suffering and to heal oneself with kindness and without judgement and self-criticism has never beed studied as a possible factor infuencing treatment adherence.

This study aims to evaluate if a link between selfcompassion and treatment adherence exists in patients suffering from schizophrenic spectrum disorders.

Study Overview

• Status: Withdrawn
• Conditions: Treatment Adherence; Selfcompassion; Schizophrenic Spectrum Disorder
• Intervention / Treatment: Other: questionnaire

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Amiens, France, 80480
    • CHU Amiens

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• patients diagnosed with schizophrenia spectrum disorder ( ICD 10 and DSM 5 criteria)
• stabilized (PANNS score under 80)
• aged 18 or above
• In case of tutor or curator, agreement of this person is requiered
• psychiatrist who's following the patient agrees with the study

Exclusion Criteria:

• underage
• non stabilized patient (PANSS score under 80 )
• patient suffering from toxic psychosis
• difficulties to understand french or cognitive impairment which are making it to difficult to answer the different self-administered questionnaires.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Average level of self compassion	The level of self compassion will be assessed with the french version of the Self-compassion scale developped and tested by K.Neff. Average scores for the Self-Compassion Scale are around 3.0 on the 1-5 Likert scale, a score of 1-2.5 indicates low self-compassion, 2.5-3.5 indicates moderate, and 3.5-5.0 is an indication of high self-compassion	one hour

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire, Amiens
• Collaborators: Crysalid center Clermont de l'Oise; CMP de Montataire; CMP de Chambly; CMP de Clermont de l'Oise; CMP de st Just en Chaussée; CMP de Senlis; CMP de Crepy en Valois; CMP de Pont St Maxence; CMP de Chantilly; CMP de Creil

Study record dates

Study Major Dates

• Study Start (Actual): September 26, 2022
• Primary Completion (Actual): July 1, 2023
• Study Completion (Actual): July 1, 2023

Study Registration Dates

• First Submitted: September 30, 2022
• First Submitted That Met QC Criteria: September 30, 2022
• First Posted (Actual): October 4, 2022

Study Record Updates

• Last Update Posted (Actual): July 20, 2023
• Last Update Submitted That Met QC Criteria: July 18, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: Treatment Adherence; Selfcompassion; schizophrenic spectrum disorder
• Additional Relevant MeSH Terms: Pathologic Processes; Disease
• Other Study ID Numbers: PI2019_843_0021

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No